Chemotherapy, immunity and microbiota—a new triumvirate?

Nature Medicine

Volumn 20, Issue 2, 2014, Pages 126-127

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER THERAPY; CHEMOTHERAPY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INTESTINE FLORA; MICROFLORA; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; BACTERIAL TRANSLOCATION; DRUG EFFECT; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; NEOPLASM; NOTE; PHYSIOLOGY; SMALL INTESTINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL TRANSLOCATION; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; INTESTINES; MICROBIOTA; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84897574679     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3473     Document Type: Article

References (14)

1. Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).
2. Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–976 (2013).
3. Grivennikov, S.I. et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17–mediated tumour growth. Nature 491, 254–258 (2012).
4. Tosolini, M. et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (TH1, TH2, Treg, TH17) in patients with colorectal cancer. Cancer Res. 71, 1263–1271 (2011).
5. Chung, A.S. et al. An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19, 1114–1123 (2013).
6. Popivanova, B.K. et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118, 560–570 (2008).
7. Pidgeon, G.P. et al. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br. J. Cancer 81, 1311–1317 (1999).
8. Taketomi, A. et al. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma before and after hepatic resection. Hepatogastroenterology 44, 477–483 (1997).
9. Mumm, J.B. et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 20, 781–796 (2011).
10. Wallace, B.D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).
11. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
12. Zitvogel, L., Galluzzi, L., Smyth, M.J. & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74–88 (2013).
13. Kottke, T. et al. Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat. Med. 19, 1625–1631 (2013).
14. Velicer, C.M. et al. Antibiotic use in relation to the risk of breast cancer. J. Am. Med. Assoc. 291, 827–835 (2004).